Home
Clinical Trials
VEGF Trap in Treating Patient...

VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer

Last Updated: 2019-07-23

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent or persistent endometrial cancer. VEGF Trap may stop the growth of endometrial cancer by blocking blood flow to the tumor and by carrying tumor-killing substances directly to endometrial cancer cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

NCT00390234

Fallopian Tube Cancer Female Reproductive Cancer Ovarian Carcinosarcoma +9 more

COMPLETED PHASE2

VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

NCT00436501

Fallopian Tube Cancer Malignant Tumor of Peritoneum Recurrent Ovarian Epithelial Cancer

COMPLETED PHASE1/PHASE2

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

NCT00327444

Ovarian Neoplasms Ascites

COMPLETED PHASE2/PHASE3

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

NCT04486352

Endometrial Cancer

RECRUITING PHASE1/PHASE2

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01132820

Endometrial Adenocarcinoma Endometrial Adenosquamous Carcinoma Endometrial Clear Cell Adenocarcinoma +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. Assess the activity of VEGF Trap in patients with recurrent or persistent endometrial cancer, in terms of the frequency of patients who have progression-free survival for at least 6 months after initiating therapy or have objective tumor response.

II. Determine the toxicity of this drug in these patients.

SECONDARY OBJECTIVES:

I. Determine the duration of progression-free survival and overall survival of patients treated with this drug.

OUTLINE:

Patients receive VEGF Trap IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Endometrial Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (aflibercept)

Patients receive VEGF Trap IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

ziv-aflibercept

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ziv-aflibercept

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

aflibercept vascular endothelial growth factor trap VEGF Trap Zaltrap

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed endometrial carcinoma, meeting both of the following criteria:

* Recurrent or persistent disease
* Refractory to curative therapy or established treatments
* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan

* Tumors within a previously irradiated field are designated as nontarget lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days after completion of radiotherapy
* Must have received one prior chemotherapeutic regimen for management of endometrial carcinoma (initial treatment may include high-dose therapy, consolidation therapy, or extended therapy administered after surgical or non-surgical assessment)
* Not a candidate for a higher priority GOG protocol
* No history or evidence of primary brain tumor or brain metastases
* GOG performance status (PS) 0-2 (patients who received 1 prior regimen) OR GOG PS 0-1 (patients who received 2 prior regimens)
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Urine protein:creatinine ratio \< 1.0 OR urine protein \< 1.0 g by 24-hour urine collection
* Creatinine ≤ 1.5 times upper limit of normal (ULN)
* Bilirubin ≤ 1.5 times ULN
* SGOT ≤ 2.5 times ULN
* Alkaline phosphatase ≤ 2.5 times ULN
* PT/PTT/INR ≤ 1.5 times ULN

* In-range INR (between 2 and 3) allowed if patient is on a stable dose of therapeutic warfarin
* QTc \< 500 msec
* No evidence of serious ventricular arrhythmia

* Ventricular tachycardia or ventricular fibrillation must be \< 3 beats in a row
* LVEF normal

* Ejection fraction ≥ 50% (for patients who received prior anthracycline, including doxorubicin hydrochloride and/or doxorubicin hydrochloride liposome)
* No clinically significant cardiovascular disease, including any of the following:

* Uncontrolled hypertension, defined as systolic blood pressure (BP) \> 140 mm Hg or diastolic BP \> 90 mm Hg
* Myocardial infarction or unstable angina within the past 6 months
* NYHA class II-IV congestive heart failure
* Serious cardiac arrhythmia requiring medication
* Peripheral vascular disease ≥ grade 2
* Cerebrovascular accident (i.e., CVA or stroke), transient ischemic attack, or subarachnoid hemorrhage within the past 6 months
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for ≥ 6 months after completion of study therapy
* No HIV positivity
* No neuropathy (sensory and motor) \> grade 1
* No active infection requiring antibiotics
* No other invasive malignancies or any evidence of other cancer within the past 5 years except for nonmelanoma skin cancer
* No serious nonhealing wound, ulcer, or bone fracture
* No history of abdominal fistula or gastrointestinal perforation
* No history or evidence of seizures not controlled with standard medical therapy
* No intra-abdominal abscess within the past 28 days
* No active bleeding or pathologic conditions that carry a high risk of bleeding (e.g., bleeding disorder, coagulopathy, or tumor involving major vessels)
* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
* No significant traumatic injury within the past 28 days
* No concurrent combination antiretroviral therapy for HIV-positive patients
* Recovered from prior surgery
* More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy and recovered
* At least 1 week since prior hormonal therapy

* Concurrent hormone replacement therapy allowed
* At least 3 weeks since any other prior therapy, including immunologic agents
* One additional prior cytotoxic regimen for management of recurrent or persistent endometrial cancer allowed

* Cytotoxic regimens include any agent that targets the genetic and/or mitotic apparatus of dividing cells, resulting in dose-limiting toxicity to the bone marrow and/or gastrointestinal mucosa
* More than 28 days since prior major surgery or open biopsy
* More than 7 days since prior minor surgery, fine needle aspirates, or core biopsies
* No prior cancer treatment that would preclude study compliance
* No prior noncytotoxic chemotherapy for management of recurrent or persistent endometrial disease
* No prior VEGF Trap or other VEGF pathway-targeted therapy
* More than 5 years since prior radiotherapy to any portion of the abdominal cavity or pelvis except for the treatment of endometrial cancer

* More than 3 years since prior radiotherapy for localized cancer of the breast, head and neck, or skin

* Patient must remain free of recurrent or metastatic disease
* More than 5 years since prior chemotherapy for any abdominal or pelvic tumor except for the treatment of endometrial cancer

* More than 3 years since prior adjuvant chemotherapy for localized breast cancer

* Patient must remain free of recurrent or metastatic disease
* Concurrent low-molecular weight heparin allowed for the prevention or treatment of venous thromboembolic disease if condition is considered clinically stable with treatment
* No other concurrent investigational agents
* No concurrent major surgery

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Coleman

Role: PRINCIPAL_INVESTIGATOR

Gynecologic Oncology Group

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hartford Hospital

Hartford, Connecticut, United States

Site Status

The Hospital of Central Connecticut

New Britain, Connecticut, United States

Site Status

Washington Hospital Center

Washington D.C., District of Columbia, United States

Site Status

Jupiter Medical Center

Jupiter, Florida, United States

Site Status

Florida Hospital

Orlando, Florida, United States

Site Status

Memorial Health University Medical Center

Savannah, Georgia, United States

Site Status

Northwestern University

Chicago, Illinois, United States

Site Status

University of Illinois

Chicago, Illinois, United States

Site Status

University of Chicago

Chicago, Illinois, United States

Site Status

Saint Vincent Hospital and Health Services

Indianapolis, Indiana, United States

Site Status

University of Iowa Hospitals and Clinics

Iowa City, Iowa, United States

Site Status

Providence Medical Center

Kansas City, Kansas, United States

Site Status

Lawrence Memorial Hospital

Lawrence, Kansas, United States

Site Status

Radiation Oncology Center of Olathe

Olathe, Kansas, United States

Site Status

Menorah Medical Center

Overland Park, Kansas, United States

Site Status

Radiation Oncology Practice Corporation Southwest

Overland Park, Kansas, United States

Site Status

Shawnee Mission Medical Center

Shawnee Mission, Kansas, United States

Site Status

Franklin Square Hospital Center

Baltimore, Maryland, United States

Site Status

Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, United States

Site Status

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, United States

Site Status

Green Bay Oncology - Escanaba

Escanaba, Michigan, United States

Site Status

Green Bay Oncology - Iron Mountain

Iron Mountain, Michigan, United States

Site Status